Screener
Aclaris Therapeutics ACRS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
FAQ
- What is Aclaris Therapeutics's retained earnings?
- Aclaris Therapeutics (ACRS) reported retained earnings of -$1.01B in Q2 2026.
- How has Aclaris Therapeutics's retained earnings changed year-over-year?
- Aclaris Therapeutics's retained earnings decreased by 8.1% year-over-year, from -$933.38M to -$1.01B.
- What is the long-term trend for Aclaris Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's retained earnings has grown at a 13.9% compound annual growth rate (CAGR), from -$504.54M to -$967.78M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Aclaris Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude